Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis
Authors:
Open Access
- 6 August 2021
- journal article
- research article
- Published by Springer Nature in Rheumatology International
- Vol. 42 (6) , 1015-1025
Abstract
Key messages: Considerable proportion of patients with SpA have been immunized to the subcutaneous anti-TNF drug they are using. Concomitant use of MTX protects from immunization, whereas SASP does not. Patients with SpA using subcutaneous anti-TNF drugs can benefit from monitoring of the drug trough levels. Immunization to biological drugs can lead to decreased efficacy and increased risk of adverse effects. The objective of this cross-sectional study was to assess the extent and significance of immunization to subcutaneous tumor necrosis factor (TNF) inhibitors in axial spondyloarthritis (axSpA) patients in real-life setting. A serum sample was taken 1–2 days before the next drug injection. Drug trough concentrations, anti-drug antibodies (ADAb) and TNF-blocking capacity were measured in 273 patients with axSpA using subcutaneous anti-TNF drugs. The clinical activity of SpA was assessed using the Bath AS Disease Activity Index (BASDAI) and the Maastricht AS Entheses Score (MASES). ADAb were found in 11% of the 273 patients: in 21/99 (21%) of patients who used adalimumab, in 0/83 (0%) of those who used etanercept, in 2/79 (3%) of those who used golimumab and in 6/12 (50%) of those who used certolizumab pegol. Use of methotrexate reduced the risk of formation of ADAb, whereas sulfasalazine did not. Presence of ADAb resulted in decreased drug concentration and reduced TNF-blocking capacity. However, low levels of ADAb had no effect on TNF-blocking capacity and did not correlate with disease activity. The drug trough levels were below the consensus target level in 36% of the patients. High BMI correlated with low drug trough concentration. Patients with low drug trough levels had higher disease activity. The presence of anti-drug antibodies was associated with reduced drug trough levels, and the patients with low drug trough levels had higher disease activity. The drug trough levels were below target level in significant proportion of patients and, thus, measuring the drug concentration and ADAb could help to optimize the treatment in SpA patients.Keywords
Funding Information
- Pfizer (WI189027)
- University of Helsinki including Helsinki University Central Hospital
This publication has 51 references indexed in Scilit:
- Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritisNature Reviews Rheumatology, 2013
- Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent mannerAnnals of the Rheumatic Diseases, 2012
- Therapeutic Drug Monitoring of Infliximab in Spondyloarthritis: An Observational Open-Label StudyTherapeutic Drug Monitoring, 2011
- Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseasesArthritis Research & Therapy, 2011
- Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative studyArthritis Research & Therapy, 2011
- The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a reviewArthritis Research & Therapy, 2010
- Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double‐blind, placebo‐controlled, phase III trialArthritis & Rheumatism, 2008
- Maintenance of infliximab treatment in ankylosing spondylitis: Results of a one‐year randomized controlled trial comparing systematic versus on‐demand treatmentArthritis & Rheumatism, 2007
- Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formationAnnals of the Rheumatic Diseases, 2007
- Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritisAnnals of the Rheumatic Diseases, 2005